{
    "root": "f369071e-c6e4-4f7d-925d-4c09eb466f75",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Methylphenidate Hydrochloride",
    "value": "20250317",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "METHYLPHENIDATE HYDROCHLORIDE",
            "code": "4B3SC438HI"
        }
    ],
    "indications": "methylphenidate hydrochloride tablets indicated treatment : attention deficit hyperactivity disorders ( adhd ) pediatric patients 6 years older adults narcolepsy",
    "contraindications": "methylphenidate hydrochloride tablets ( 2.2 ) : pediatric patients 6 years older : start 5 mg twice daily ( breakfast lunch ) , titrating dose weekly 5- 10-mg increments . dosages 60 mg/day recommended . adults : average daily 20 mg 30 mg , administered 2 3 times daily , preferably 30 45 minutes meals . maximum total daily 60 mg ( 2.2 ) .",
    "warningsAndPrecautions": "methylphenidate hydrochloride tablets , usp 5 mg : light purple , round-shaped , flat faced , beveled edge , uncoated tablets , debossed `` 228 `` one side s5 side . ndc 63629-1172-1 bottles 100 store 20°c 25°c ( 68°f 77°f ) , excursions permitted 15°c 30°c ( 59°f 86°f ) . [ usp controlled room temperature ] . protect light . dispense tight , light-resistant container ( usp ) child-resistant closure . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "hypersensitivity methylphenidate components methylphenidate hydrochloride tablets . hypersensitivity , angioedema anaphylactic , reported patients treated methylphenidate [ ( 6.1 ) ] . concomitant treatment monoamine oxidase inhibitors ( maois ) , within 14 days following discontinuation treatment maoi , risk hypertensive crises [ ( 7.1 ) ] .",
    "indications_original": "Methylphenidate hydrochloride tablets are indicated for the treatment of:\n                  \n                     Attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults\n                     Narcolepsy",
    "contraindications_original": "Methylphenidate Hydrochloride Tablets (2.2) : Pediatric Patients 6 Years and Older: Start with 5 mg twice daily (before breakfast and lunch), titrating the dose weekly in 5- to 10-mg increments. Dosages above 60 mg/day are not recommended. Adults: Average daily dosage is 20 mg to 30 mg, administered 2 or 3 times daily, preferably 30 to 45 minutes before meals. Maximum total daily dosage is 60 mg (2.2) .",
    "warningsAndPrecautions_original": "Methylphenidate Hydrochloride Tablets, USP\n                  \n                  5 mg: Light purple, round-shaped, flat faced, beveled edge, uncoated tablets, debossed with \"228\" on one side and S5 on the other side.\n                  \n                     NDC 63629-1172-1 Bottles of 100\n                  \n                  Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F). [See USP controlled room temperature].\n                  Protect from light.\n                  Dispense in tight, light-resistant container (USP) with a child-resistant closure.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride tablets. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported in patients treated with methylphenidate\n  \n   [\n   \n    see Adverse Reactions (6.1)].\n  \n   \n                     \n                     Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises\n  \n   [\n   \n    see Drug Interactions (7.1)]."
}